Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma.

Ang JE, Pal A, Asad YJ, Henley AT, Valenti M, Box G, de Haven Brandon A, Revell VL, Skene DJ, Venturi M, Rueger R, Meresse V, Eccles SA, de Bono JS, Kaye SB, Workman P, Banerji U, Raynaud FI.

Mol Cancer Ther. 2017 Oct;16(10):2315-2323. doi: 10.1158/1535-7163.MCT-16-0881. Epub 2017 Jun 21.

PMID:
28637716
2.

Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.

Weidle UH, Birzele F, Kollmorgen G, Rueger R.

Cancer Genomics Proteomics. 2016 11-12;13(6):407-423. Review.

3.

Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.

Reis B, Jukofsky L, Chen G, Martinelli G, Zhong H, So WV, Dickinson MJ, Drummond M, Assouline S, Hashemyan M, Theron M, Blotner S, Lee JH, Kasner M, Yoon SS, Rueger R, Seiter K, Middleton SA, Kelly KR, Vey N, Yee K, Nichols G, Chen LC, Pierceall WE.

Haematologica. 2016 May;101(5):e185-8. doi: 10.3324/haematol.2015.139717. Epub 2016 Feb 11. No abstract available.

4.

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.

Andreeff M, Kelly KR, Yee K, Assouline S, Strair R, Popplewell L, Bowen D, Martinelli G, Drummond MW, Vyas P, Kirschbaum M, Iyer SP, Ruvolo V, González GM, Huang X, Chen G, Graves B, Blotner S, Bridge P, Jukofsky L, Middleton S, Reckner M, Rueger R, Zhi J, Nichols G, Kojima K.

Clin Cancer Res. 2016 Feb 15;22(4):868-76. doi: 10.1158/1078-0432.CCR-15-0481. Epub 2015 Oct 12.

5.

Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor.

Stahl S, da Silva Mateus Seidl AR, Ducret A, Kux van Geijtenbeek S, Michel S, Racek T, Birzele F, Haas AK, Rueger R, Gerg M, Niederfellner G, Pastan I, Brinkmann U.

Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10732-7. doi: 10.1073/pnas.1512863112. Epub 2015 Aug 10.

6.

MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia.

Zhong H, Chen G, Jukofsky L, Geho D, Han SW, Birzele F, Bader S, Himmelein L, Cai J, Albertyn Z, Rothe M, Essioux L, Burtscher H, Middleton SA, Rueger R, Chen LC, Dangl M, Nichols G, Pierceall WE.

Br J Haematol. 2015 Nov;171(3):432-5. doi: 10.1111/bjh.13411. Epub 2015 Apr 8. No abstract available.

7.

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, Heil F, Rueger R, Graves B, Ding M, Geho D, Middleton SA, Vassilev LT, Nichols GL, Bui BN.

Lancet Oncol. 2012 Nov;13(11):1133-40. doi: 10.1016/S1470-2045(12)70474-6. Epub 2012 Oct 17.

PMID:
23084521
8.

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

Leijen S, Middleton MR, Tresca P, Kraeber-Bodéré F, Dieras V, Scheulen ME, Gupta A, Lopez-Valverde V, Xu ZX, Rueger R, Tessier JJ, Shochat E, Blotner S, Naegelen VM, Schellens JH, Eberhardt WE.

Clin Cancer Res. 2012 Sep 1;18(17):4794-805. Epub 2012 Jul 5.

9.

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.

Martinez-Garcia M, Banerji U, Albanell J, Bahleda R, Dolly S, Kraeber-Bodéré F, Rojo F, Routier E, Guarin E, Xu ZX, Rueger R, Tessier JJ, Shochat E, Blotner S, Naegelen VM, Soria JC.

Clin Cancer Res. 2012 Sep 1;18(17):4806-19. Epub 2012 Jul 3.

10.

Automated brightfield dual-color in situ hybridization for detection of mouse double minute 2 gene amplification in sarcomas.

Zhang W, McElhinny A, Nielsen A, Wang M, Miller M, Singh S, Rueger R, Rubin BP, Wang Z, Tubbs RR, Nagle RB, Roche P, Wu P, Pestic-Dragovich L.

Appl Immunohistochem Mol Morphol. 2011 Jan;19(1):54-61. doi: 10.1097/PAI.0b013e3181ee8e14.

PMID:
20881839
11.

The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of RO5068760, an MEK inhibitor, in healthy volunteers: assessment of target suppression.

Lee L, Niu H, Goelzer P, Rueger R, Deutsch J, Busse-Reid R, DeSchepper S, Blotner S, Barrett J, Weissgerber G, Peck R.

J Clin Pharmacol. 2010 Dec;50(12):1397-405. doi: 10.1177/0091270010361254. Epub 2010 Apr 12.

PMID:
20386016
12.

The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker.

Lee L, Niu H, Rueger R, Igawa Y, Deutsch J, Ishii N, Mu S, Sakamoto Y, Busse-Reid R, Gimmi C, Goelzer P, De Schepper S, Yoshimura Y, Barrett J, Ishikawa Y, Weissgerber G, Peck R.

Clin Cancer Res. 2009 Dec 1;15(23):7368-74. doi: 10.1158/1078-0432.CCR-09-1696. Epub 2009 Nov 24.

13.

Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients.

Berkofsky-Fessler W, Nguyen TQ, Delmar P, Molnos J, Kanwal C, DePinto W, Rosinski J, McLoughlin P, Ritland S, DeMario M, Tobon K, Reidhaar-Olson JF, Rueger R, Hilton H.

Mol Cancer Ther. 2009 Sep;8(9):2517-25. doi: 10.1158/1535-7163.MCT-09-0083. Epub 2009 Sep 15.

14.

[Sonography of the adrenal glands].

Rüeger R.

Praxis (Bern 1994). 2005 Mar 2;94(9):343-8. Review. German.

PMID:
15796463
15.
16.

Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis.

Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL.

Clin Cancer Res. 2001 Apr;7(4):1043-51.

17.

Effects of arachidonic acid metabolites in a murine model of squamous cell carcinoma.

Scioscia KA, Snyderman CH, D'Amico F, Comsa S, Rueger R, Light B.

Head Neck. 2000 Mar;22(2):149-55.

PMID:
10679902
18.

Reduced postoperative infections with an immune-enhancing nutritional supplement.

Snyderman CH, Kachman K, Molseed L, Wagner R, D'Amico F, Bumpous J, Rueger R.

Laryngoscope. 1999 Jun;109(6):915-21.

PMID:
10369282
19.

1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo.

Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS.

Cancer Res. 1999 Jun 1;59(11):2644-9.

20.

Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal antiinflammatory drugs.

Scioscia KA, Snyderman CH, Rueger R, Reddy J, D'Amico F, Comsa S, Collins B.

Am J Otolaryngol. 1997 Jan-Feb;18(1):1-8.

PMID:
9006670
21.

Thymic cysts.

Weber PC, Rueger RG, Pickeral J.

Am J Otolaryngol. 1996 Jan-Feb;17(1):64-6. No abstract available.

PMID:
8801820
22.

Tumor angiogenesis as a predictor of tumor aggressiveness and metastatic potential in squamous cell carcinoma of the head and neck.

Carrau RL, Barnes EL, Snyderman CH, Petruzzelli G, Kachman K, Rueger R, D'Amico F, Johnson JT.

Invasion Metastasis. 1995;15(5-6):197-202.

PMID:
8765194
23.

Professional burnout among head and neck surgeons: results of a survey.

Johnson JT, Wagner RL, Rueger RM, Goepfert H.

Head Neck. 1993 Nov-Dec;15(6):557-60.

PMID:
8253565
24.

Isolated sphenoid sinus disease.

Rothfield RE, de Vries EJ, Rueger RG.

Head Neck. 1991 May-Jun;13(3):208-12.

PMID:
2037472
25.

Extracranial carotid artery aneurysm: an unusual neck mass in a young adult.

Cunningham MJ, Rueger RG, Rothfus WE.

Ann Otol Rhinol Laryngol. 1989 May;98(5 Pt 1):396-9. No abstract available.

PMID:
2719456
26.

Hemimacroglossia and unilateral ischemic necrosis of the tongue in a long-duration neurosurgical procedure.

Teeple E, Maroon J, Rueger R.

Anesthesiology. 1986 Jun;64(6):845-6. No abstract available.

PMID:
3717665
27.

Lip reconstruction: Karapandzic flap revisited.

Mandell-Brown M, Schwartz K, Rueger RG.

Trans Pa Acad Ophthalmol Otolaryngol. 1986;38(2):449-53. No abstract available.

PMID:
3824450
28.

[Risk profile and prognosis after myocardial infarct complicated by ventricular fibrillation].

Frey M, Rüeger R, Pfisterer M, Erne P, Steinmann E, Müller-Brand J, Emmenegger H, Burkart F.

Schweiz Med Wochenschr. 1985 Nov 9;115(45):1624-6. German.

PMID:
4081694
29.

Pharyngogastric reconstruction after esophago-pharyngolaryngectomy for carcinoma of the hypopharynx and cervical esophagus.

Effron MZ, Myers EN, Rueger RG.

Trans Pa Acad Ophthalmol Otolaryngol. 1979 Fall;32(2):166-70. No abstract available.

PMID:
524425
30.

Benign disease of the thyroid gland and vocal cord paralysis.

Rueger RG.

Laryngoscope. 1974 Jun;84(6):897-907. No abstract available.

PMID:
4832372
31.

The superior laryngeal nerve and the interarytenoid muscle in humans: an anatomical study.

Rueger RS.

Laryngoscope. 1972 Nov;82(11):2008-31. No abstract available.

PMID:
5081741
32.

Parapharyngeal neurilemoma with intracranial extension.

Smith RO Jr, Rueger RG.

South Med J. 1972 Oct;65(10):1171-5. No abstract available.

PMID:
5074086
33.

Unusual complications following cervical esophagostomy.

Smith R, Rueger RG.

Pa Med. 1972 Feb;75(2):71-2. No abstract available.

PMID:
4625371
34.

[A safe anesthesic technic in endoscopy using methoxyflurane].

Zsigmond EK, Rueger RG.

Rev Bras Anestesiol. 1969 Jul-Sep;19(3):416-24. Portuguese. No abstract available.

PMID:
5382269
35.

Endoscopy under general anesthesia.

SILVERBLATT BL, RUEGER RG.

Laryngoscope. 1963 Jun;73:749-54. No abstract available.

PMID:
13992933
36.

Spleen grafts upon the heart: effect upon intercoronary blood flow.

LEIGHNINGER DS, BECK CS, RUEGER R, EGUCHI S.

J Thorac Cardiovasc Surg. 1963 Mar;45:412-7. No abstract available.

PMID:
13929430
37.

Effect of pentaerythritol tetranitrate, amyl nitrite and alcohol on arterial blood supply to ischemic myocardium.

LEIGHNINGER DS, RUEGER R, BECK CS.

Am J Cardiol. 1961 Apr;7:533-7. No abstract available.

PMID:
13760550
38.

Effect of pentaerythriol tetranitrate, amyl nitrite and alcohol on arterial blood supply to ischemic myocardium.

LEIGHNINGER DS, RUEGER R, BECK CS.

Am J Cardiol. 1961 Apr;7:533-7. No abstract available.

PMID:
13760549
39.

Intercoronary arterial channels produced by chemical agents.

LEIGHNINGER DS, EINSEL IH, RUEGER RG, BECK CS.

Am J Cardiol. 1960 Nov;6:949-51. No abstract available.

PMID:
13760547
40.

Ligation of internal mammary arteries as related to the coronary artery circulation.

RUEGER RG, LEIGHNINGER DS, RISH L, CHEN YC.

Am J Cardiol. 1960 Nov;6:946-8. No abstract available.

PMID:
13744538
41.

Effect of glyceryl trinitrate (nitroglycerin) on arterial blood supply to ischemic myocardium.

LEIGHNINGER DS, RUEGER R, BECK CS.

Am J Cardiol. 1959 May;3(5):638-46. No abstract available.

PMID:
13649589

Supplemental Content

Loading ...
Support Center